세계의 브랜드 제네릭 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향 예측(2024-2032년)

The global demand for Branded Generics Market is presumed to reach the market size of nearly USD 502.23 Billion by 2032 from USD 289.31 Billion in 2023 with a CAGR of 6.32% under the study period 2024-2032.

Branded generics refer to generic drugs that have been provided with a market name. They are generally marketed akin to the way branded drugs are. In comparison, ordinary generic drugs are usually known by their chemical names. However, branded generics are advantageous as they promote consumer loyalty and drive recognition. Some branded generics are also made particularly as novel dosage forms of off-patent drugs. Filling in a dosage gap while simultaneously providing consumers a name that is easy to remember than the true generic name is the most significant advantage of branded generics.

MARKET DYNAMICS

Branded generics have several advantages, including manufacturers' ability to get name recognition and higher costs than ordinary generics. They are a cheaper alternative to branded drugs and often work towards releasing savings. Further, the product is slowly gaining popularity due to efficacy, trusted quality, and differentiated products. They are showing growth in low-and middle-income countries like China, India, Chile, etc. as well and are currently considered a small but profitable subset of the whole generic market. However, it needs to be noted that if they are not co-formulated, higher pill burdens may discourage adherence. Further, the problem with the product is that their appearance can at times change if the pharmacy producing the medicine changes as well. This can confuse consumers.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Branded Generics. The growth and trends of Branded Generics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Branded Generics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

• Alkylating Agents
• Antimetabolites
• Hormones
• Anti-Hypertensive
• Lipid Lowering Drugs
• Anti-Depressants
• Anti-Psychotics
• Anti-Epileptics
• Others

By Application

• Oncology
• Cardiovascular Diseases
• Neurological Diseases
• Gastrointestinal Diseases
• Dermatological Diseases
• Acute And Chronic Pain
• Others

By Topical

• Oral
• Parenteral
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Branded Generics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Branded Generics market include Teva Pharmaceutical Industries Ltd., Lupin, Sanofi, Sun Pharmaceutical Industries Ltd., Dr. Reddy'S Laboratories Ltd., Endo International Plc, GlaxoSmithKline Plc, Pfizer Inc., Apotex Inc., Viatris Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. BRANDED GENERICS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Drug Class
  • 3.7.2 Market Attractiveness Analysis By Application
  • 3.7.3 Market Attractiveness Analysis By Topical
  • 3.7.4 Market Attractiveness Analysis By Distribution Channel
  • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL BRANDED GENERICS MARKET ANALYSIS BY DRUG CLASS

• 5.1. Overview By Drug Class
• 5.2. Historical and Forecast Data Analysis By Drug Class
• 5.3. Alkylating Agents Historic and Forecast Sales By Regions
• 5.4. Antimetabolites Historic and Forecast Sales By Regions
• 5.5. Hormones Historic and Forecast Sales By Regions
• 5.6. Anti-Hypertensive Historic and Forecast Sales By Regions
• 5.7. Lipid Lowering Drugs Historic and Forecast Sales By Regions
• 5.8. Anti-Depressants Historic and Forecast Sales By Regions
• 5.9. Anti-Psychotics Historic and Forecast Sales By Regions
• 5.10. Anti-Epileptics Historic and Forecast Sales By Regions
• 5.11. Others Historic and Forecast Sales By Regions

6. GLOBAL BRANDED GENERICS MARKET ANALYSIS BY APPLICATION

• 6.1. Overview By Application
• 6.2. Historical and Forecast Data Analysis By Application
• 6.3. Oncology Historic and Forecast Sales By Regions
• 6.4. Cardiovascular Diseases Historic and Forecast Sales By Regions
• 6.5. Neurological Diseases Historic and Forecast Sales By Regions
• 6.6. Gastrointestinal Diseases Historic and Forecast Sales By Regions
• 6.7. Dermatological Diseases Historic and Forecast Sales By Regions
• 6.8. Acute And Chronic Pain Historic and Forecast Sales By Regions
• 6.9. Others Historic and Forecast Sales By Regions

7. GLOBAL BRANDED GENERICS MARKET ANALYSIS BY TOPICAL

• 7.1. Overview By Topical
• 7.2. Historical and Forecast Data Analysis By Topical
• 7.3. Oral Historic and Forecast Sales By Regions
• 7.4. Parenteral Historic and Forecast Sales By Regions
• 7.5. Others Historic and Forecast Sales By Regions

8. GLOBAL BRANDED GENERICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 8.1. Overview By Distribution Channel
• 8.2. Historical and Forecast Data Analysis By Distribution Channel
• 8.3. Hospital Pharmacy Historic and Forecast Sales By Regions
• 8.4. Retail Pharmacy Historic and Forecast Sales By Regions
• 8.5. Online Pharmacy Historic and Forecast Sales By Regions

9. GLOBAL BRANDED GENERICS MARKET ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook
• 9.2. Introduction
• 9.3. North America Sales Analysis
  • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.3.2 North America By Segment Sales Analysis
  • 9.3.3 North America By Country Sales Analysis
  • 9.3.4 United States Sales Analysis
  • 9.3.5 Canada Sales Analysis
  • 9.3.6 Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.4.2 Europe By Segment Sales Analysis
  • 9.4.3 Europe By Country Sales Analysis
  • 9.4.4 United Kingdom Sales Analysis
  • 9.4.5 France Sales Analysis
  • 9.4.6 Germany Sales Analysis
  • 9.4.7 Italy Sales Analysis
  • 9.4.8 Russia Sales Analysis
  • 9.4.9 Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.5.2 Asia Pacific By Segment Sales Analysis
  • 9.5.3 Asia Pacific By Country Sales Analysis
  • 9.5.4 China Sales Analysis
  • 9.5.5 India Sales Analysis
  • 9.5.6 Japan Sales Analysis
  • 9.5.7 South Korea Sales Analysis
  • 9.5.8 Australia Sales Analysis
  • 9.5.9 South East Asia Sales Analysis
  • 9.5.10 Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.6.2 Latin America By Segment Sales Analysis
  • 9.6.3 Latin America By Country Sales Analysis
  • 9.6.4 Brazil Sales Analysis
  • 9.6.5 Argentina Sales Analysis
  • 9.6.6 Peru Sales Analysis
  • 9.6.7 Chile Sales Analysis
  • 9.6.8 Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.7.2 Middle East & Africa By Segment Sales Analysis
  • 9.7.3 Middle East & Africa By Country Sales Analysis
  • 9.7.4 Saudi Arabia Sales Analysis
  • 9.7.5 UAE Sales Analysis
  • 9.7.6 Israel Sales Analysis
  • 9.7.7 South Africa Sales Analysis
  • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE BRANDED GENERICS COMPANIES

• 10.1. Branded Generics Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11. COMPANY PROFILES OF BRANDED GENERICS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Market Concentration Rate
• 11.3. Teva Pharmaceutical Industries Ltd.
  • 11.3.1 Company Overview
  • 11.3.2 Company Revenue
  • 11.3.3 Products
  • 11.3.4 Recent Developments
• 11.4. Lupin
  • 11.4.1 Company Overview
  • 11.4.2 Company Revenue
  • 11.4.3 Products
  • 11.4.4 Recent Developments
• 11.5. Sanofi
  • 11.5.1 Company Overview
  • 11.5.2 Company Revenue
  • 11.5.3 Products
  • 11.5.4 Recent Developments
• 11.6. Sun Pharmaceutical Industries Ltd.
  • 11.6.1 Company Overview
  • 11.6.2 Company Revenue
  • 11.6.3 Products
  • 11.6.4 Recent Developments
• 11.7. Dr. Reddy'S Laboratories Ltd.
  • 11.7.1 Company Overview
  • 11.7.2 Company Revenue
  • 11.7.3 Products
  • 11.7.4 Recent Developments
• 11.8. Endo International Plc
  • 11.8.1 Company Overview
  • 11.8.2 Company Revenue
  • 11.8.3 Products
  • 11.8.4 Recent Developments
• 11.9. GlaxoSmithKline Plc
  • 11.9.1 Company Overview
  • 11.9.2 Company Revenue
  • 11.9.3 Products
  • 11.9.4 Recent Developments
• 11.10. Pfizer Inc.
  • 11.10.1 Company Overview
  • 11.10.2 Company Revenue
  • 11.10.3 Products
  • 11.10.4 Recent Developments
• 11.11. Apotex Inc.
  • 11.11.1 Company Overview
  • 11.11.2 Company Revenue
  • 11.11.3 Products
  • 11.11.4 Recent Developments
• 11.12. Viatris Inc
  • 11.12.1 Company Overview
  • 11.12.2 Company Revenue
  • 11.12.3 Products
  • 11.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies